Our Pricing

How Does Wegovy Work: Proven Clinical Trial Results

Understanding how does Wegovy work UK clinical trials have demonstrated is essential before starting treatment. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural gut hormones to regulate appetite and food intake, with STEP clinical trials showing average weight reductions of 15% over 68 weeks [1]. At Cured Pharmacy, our UK-registered clinical team provides evidence-based consultations to determine if Wegovy is suitable for your weight management goals.

The Mechanism: How Wegovy Works in Your Body

Wegovy contains semaglutide 2.4mg, a synthetic version of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in your intestines after eating [1]. When injected once weekly, semaglutide binds to GLP-1 receptors in multiple areas including the brain's appetite centres, the pancreas, and the stomach, triggering a cascade of metabolic effects that support weight loss.

The primary mechanisms include slowing gastric emptying (making you feel fuller for longer), reducing appetite signals in the hypothalamus, and improving insulin secretion whilst suppressing glucagon release [2]. Unlike stimulant-based weight loss medications, Wegovy works with your body's natural satiety pathways rather than artificially speeding metabolism, which contributes to its favourable safety profile observed in clinical trials.

Semaglutide has a half-life of approximately one week, allowing for once-weekly subcutaneous injections that maintain steady therapeutic levels [1]. This extended action is achieved through structural modifications that prevent rapid breakdown by enzymes, making it significantly more convenient than older daily injectable treatments.

STEP Clinical Trial Results: The Evidence Base

The STEP (Semaglutide Treatment Effect in People with obesity) programme comprised five landmark trials involving over 4,500 participants across multiple countries, providing the robust evidence that led to Wegovy's MHRA licensing in the UK [1][2]. These randomised, double-blind, placebo-controlled trials represent the gold standard in clinical research.

In the pivotal STEP 1 trial, adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition received either Wegovy 2.4mg or placebo alongside lifestyle intervention for 68 weeks [1]. Participants on Wegovy achieved an average weight reduction of 14.9% compared to 2.4% with placebo, with 86.4% of Wegovy-treated patients losing at least 5% of their body weight versus 31.5% on placebo.

STEP 2 specifically examined patients with type 2 diabetes, demonstrating an average 9.6% weight loss with Wegovy versus 3.4% with placebo, alongside improvements in HbA1c levels [2]. STEP 3 combined Wegovy with intensive behavioural therapy, achieving average weight reductions of 16.0%, whilst STEP 4 assessed weight maintenance after initial loss, showing sustained results over 68 weeks of continued treatment.

Long-Term Efficacy and Weight Maintenance

The STEP 4 trial provided crucial evidence on long-term weight maintenance, a historically challenging aspect of obesity treatment [3]. Participants who achieved weight loss during a 20-week run-in period were randomised to either continue Wegovy or switch to placebo for a further 48 weeks. Those continuing Wegovy maintained and extended their weight loss (average additional 7.9% reduction), whilst the placebo group regained an average 6.9% of body weight, demonstrating the medication's role in sustained weight management [3].

Wegovy Dosing Schedule: The Gradual Titration Approach

Wegovy treatment follows a carefully designed dose-escalation schedule over 16-20 weeks to optimise tolerability and minimise gastrointestinal side effects [4]. Your UK prescriber will start you on 0.25mg once weekly for four weeks, then increase monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly.

This gradual titration is clinically important — it allows your digestive system to adapt to semaglutide's effects on gastric emptying, significantly reducing the likelihood of nausea, vomiting, and diarrhoea that can occur with rapid dose increases [4]. In clinical trials, approximately 5% of participants discontinued due to gastrointestinal adverse events, with most occurring during the escalation phase.

Each Wegovy pen is pre-filled with a single dose and features a hidden needle for discreet, straightforward subcutaneous injection into the abdomen, thigh, or upper arm. The injection site should be rotated weekly to prevent lipohypertrophy. At Cured Pharmacy, your medication is supplied with comprehensive patient information leaflets and injection guidance to ensure proper administration technique.

Who Can Use Wegovy: UK Prescribing Criteria

In the UK, Wegovy is licensed for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea [4]. NICE guidance recommends considering GLP-1 receptor agonists as part of a specialist weight management service for appropriate patients.

Before prescribing, your UK clinician will assess contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and diabetic retinopathy requiring active treatment [4]. Wegovy is not recommended during pregnancy or breastfeeding, and effective contraception should be used during treatment and for two months after discontinuation.

All Wegovy prescriptions at Cured Pharmacy require completion of a clinical assessment by our UK-registered prescribers, who will review your medical history, current medications, and weight management goals. This ensures treatment is clinically appropriate and safe for your individual circumstances, in line with MHRA and GPhC regulations governing prescription-only medicines.

Monitoring and Follow-Up Requirements

Effective weight management with Wegovy requires ongoing clinical monitoring to assess response, tolerability, and the need for dose adjustments. NICE recommends reviewing treatment effectiveness after 6-12 months, with continuation dependent on achieving at least 5% weight loss alongside lifestyle modifications [4]. Your prescriber may also monitor cardiovascular risk factors, HbA1c levels if you have diabetes, and any emerging side effects throughout treatment.

Common Side Effects and Management Strategies

The most frequently reported side effects in STEP trials were gastrointestinal, including nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%), with most cases being mild to moderate and diminishing over time [1][2]. These effects result from semaglutide's action on gastric emptying and are typically most pronounced during dose escalation.

Practical management strategies include eating smaller, more frequent meals, avoiding high-fat and spicy foods, staying well-hydrated, and taking the injection on the same day each week with or without food [4]. If nausea persists, your prescriber may slow the titration schedule or temporarily maintain a lower dose until tolerance improves. Severe or persistent vomiting requires medical review to prevent dehydration.

Less common but important side effects include injection site reactions (redness, itching), increased heart rate, fatigue, and dysgeusia (altered taste). Hypoglycaemia is uncommon with Wegovy monotherapy but may occur if you're taking other glucose-lowering medications [4]. Rare but serious risks include pancreatitis (discontinue immediately if severe abdominal pain occurs), gallbladder disease, and acute kidney injury secondary to dehydration from gastrointestinal effects.

How Does Wegovy Work Compared to Other Weight Loss Treatments

Wegovy represents a significant advancement over earlier pharmacological weight loss options available in the UK. Orlistat, a lipase inhibitor that reduces fat absorption, typically produces 3-5% weight loss but causes frequent gastrointestinal side effects including steatorrhoea [5]. Naltrexone-bupropion (Mysimba) works on central appetite pathways but shows more modest efficacy (average 5-6% weight loss) and has contraindications in uncontrolled hypertension and seizure disorders.

Compared to Saxenda (liraglutide 3mg), an earlier GLP-1 receptor agonist requiring daily injections, Wegovy demonstrates superior efficacy — STEP trials showed approximately 15% weight loss versus 8% with liraglutide in comparative analyses [1][5]. The once-weekly dosing also significantly improves treatment adherence, a critical factor in long-term weight management success.

Newer dual GIP/GLP-1 receptor agonists show even greater weight reductions in clinical trials, but Wegovy remains the most extensively studied GLP-1 treatment with robust long-term safety data spanning multiple years [1][2][3]. At Cured Pharmacy, our clinical team can discuss which licensed treatment aligns best with your medical history, lifestyle preferences, and weight loss goals during your confidential online consultation.

Combining Wegovy with Lifestyle Modifications

Clinical trials demonstrate that Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity [1][2]. The STEP programme included lifestyle counselling sessions every four weeks, and this integrated approach is recommended in UK clinical practice. Wegovy facilitates adherence to dietary changes by reducing appetite and food cravings, but sustainable weight loss requires behavioural modifications that extend beyond pharmacotherapy alone.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
4. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and cannot be supplied without a valid prescription from a UK prescriber following clinical consultation.